We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Paul
Benn
HIV
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Post-exposure prophylaxis (PEP) involves taking anti-HIV medications as soon as possible after you may have been exposed to HIV to try to reduce the chance of becoming HIV positive. It is readily available for healthcare workers following occupational HIV exposure (during the performance of their job duties). The current Department of Health guidelines recommend treatment with combination of three drugs for 28 days, which should be started as soon as possible after the exposure, ideally within one hour. Post-exposure prophylaxis following non-occupational exposure to HIV (e.g., sexual contact, sharing of injection drug needles) is increasingly being provided and many countries including the UK have now developed guidelines for its use. However, studies also suggest that PEP is often poorly tolerated, with patients frequently reporting side effects and not completing their treatment. Identifying drug combinations likely to be better tolerated would therefore be extremely useful. The aim of this study is to determine if, when used in combination with tenofovir/emtricitabine, maraviroc is superior to lopinavir/ritonavir with respect to the proportion of patients who complete 28 days of PEP without developing adverse events.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2017 Results article in https://www.ncbi.nlm.nih.gov/pubmed/28369381 results
You can take part if:
You may not be able to take part if:
1. The baseline human immunodeficiency virus (HIV) test is reactive or positive2. Currently receiving medication which would reduce the effectiveness of Kaletra® / maraviroc 3. Currently receiving medication where the interaction would result in a dangerously high level of the concomitant drug4. Pregnant or trying to become pregnant at the time of trial entry5. The source is known to have multi-drug resistant HIV and therefore more likely to have CXCR 4 tropic virus6. History of active substance abuse or psychiatric illness that, in the opinion of the investigator, would preclude compliance with the protocol, dosing schedule or assessments7. Any other active clinically significant condition, or findings during screening medical history or examination, or abnormality on screening laboratory blood tests that would, in the opinion of the investigator, compromise the patients safety or outcome in the trial
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Paul
Benn
The study is sponsored by Central and North West London NHS Foundation Trust (UK) and funded by Pfizer (UK) ref: WS923309.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
